

Sponsored by:



In partnership with the:



**Controlling the HIV Epidemic with Antiretrovirals: Treatment as Prevention and Pre-Exposure Prophylaxis**  
**11-12 June 2012 • Royal Garden Hotel, London**

<b>11-Jun-12</b>	
<b>0800-0815</b>	<b>Welcome by Conference Co-Hosts</b> <i>José M. Zuniga, PhD, MPH* (IAPAC), Jane Anderson, PhD* (BHIVA)</i>  <b>Welcome by Conference Co-Chairs</b> <i>Brian Gazzard, MD* (Chelsea &amp; Westminster Hospital), Kenneth Mayer, MD* (Harvard University)</i>
<b>0815-0845</b>	<b>Keynote Address: Combination Prevention - Public Health and Human Rights Imperatives</b> <i>Gottfried Hirnschall, MD* (WHO)</i>
<b>Treatment as Prevention (TasP)</b>	
<b>0845-0930</b>	<b>Panel 1: Review of Current TasP Studies</b> <b>Moderator:</b> <i>Papa Salif Sow, MD* (University of Dakar)</i> <i>James Hakim, MD* (University of Zimbabwe)</i> <i>Victor De Gruttola, ScD* (Harvard University)</i> <i>Sarah J. Fidler, MBBS, PhD* (Imperial College, London)</i>
<b>0930-0950</b>	<b>Plenary 1: Perspectives from the Vancouver TasP Workshop</b> <i>Julio Montaner, MD* (University of British Columbia)</i>
<b>0950-1035</b>	<b>Panel 2: Facilitating Access to TasP from Bench to Clinic</b> <b>Moderator:</b> <i>Mauro Schechter, MD* (Federal University of Rio de Janeiro)</i> <i>Michael Norton, MPAS* (Abbott Laboratories)</i> <i>John Pottage, MD* (ViiV Healthcare)</i> <i>Jim Rooney, MD* (Gilead Sciences)</i> <i>Additional Pharma Reps TBA</i>
<b>1035-1135</b>	<b>Discussion</b>

<b>1135-1205</b>	<b>Coffee Break</b>
<b>1205-1225</b>	<b>Plenary 2: TasP - Individual versus Public Health Benefit versus Both</b> <i>Paul Kasonkomona (OXFAM Civil Society Health Forum, Lusaka, Zambia)</i>
<b>1225-1245</b>	<b>Plenary 3: Health System Concerns Related to TasP and MARPs</b> <i>Valerie Delpech, MD, MPH* (UK Health Protection Agency)</i>
<b>1245-1305</b>	<b>Plenary 4: TasP in the Context of HIV/TB Coinfection</b> <i>Robin Wood, MBChB* (Stellenbosch University)</i>
<b>1305-1405</b>	<b>Lunch</b>
<b>1405-1450</b>	<b>Panel 3: Implementing TasP - Addressing Clinical and Other Concerns</b> <b>Moderator:</b> <i>Bertrand Audoin (International AIDS Society)</i> <i>Ceri Evans* (Chelsea &amp; Westminster Hospital) - protocols, surveillance</i> <i>Gus Cairns* (European AIDS Treatment Group) - community perspective</i> <i>Ian Williams, MD* (University College London) - adherence, resistance</i> <i>Robert Carroll, RN* (Association of Nurses in AIDS Care) - health workforce perspective</i> <i>TBD (UK Medical Research Council) - impact evaluation</i>
<b>1450-1510</b>	<b>Plenary 5: Cost-Benefit Analysis of Universal versus Incremental TasP</b> <i>Bernard Schwartzlander, MD* (UNAIDS)</i>
<b>1510-1530</b>	<b>Plenary 6: Ethical Standards vis-à-vis Prevention in Biomedical Prevention Trials</b> <i>Jeremy Sugarman, MD, MPH* (Johns Hopkins University)</i>
<b>1530-1630</b>	<b>Discussion</b>
<b>1630-1715</b>	<b>Panel 4: Implementing Universal TasP - Wishful Thinking?</b> <b>Moderator:</b> <i>Nikos Dedes* (Postive Voice, Athens, Greece)</i> <i>Eric Fleutelot* (Sidaction) - human rights considerations</i> <i>Peter Cherutich, MD, MPH* (National AIDS/STD Control Program, Kenya) - budgetary constraints</i> <i>Helen Rees, MD* (University of Witwatersrand, South Africa) - public health considerations</i>
<b>1715-1815</b>	<b>Discussion</b>
<b>1830-2030</b>	<b>Opening Reception</b>

<b>12-Jun-12</b>	
<b>Pre-Exposure Prophylaxis (PrEP)</b>	
<b>0800-0820</b>	<b>Plenary 7: PrEP - Current Global Themes and Future Directions</b> <i>Kenneth Mayer, MD* (Harvard University)</i>

0820-0840	<b>Plenary 8: Antiretroviral Pharmacology for PrEP</b> <i>Craig Hendrix, MD* (Johns Hopkins University)</i>
0840-0925	<b>Panel 5: Review of Current PrEP Studies</b> <b>Moderator:</b> <i>Yvette Calderdon, MD, MS* (Albert Einstein College of Medicine)</i> <i>Linda Gail-Bekker, MBChB, PhD* (University of Cape Town)</i> <i>Roy M. Gulick, MD* (Cornell University)</i> <i>Sheena McCormack, MSc* (UK Medical Research Council)</i> <i>Ian McGowan, MD, PhD* (University of Pittsburgh)</i> <i>Bruno Spire, MD, PhD* (INSERM, U912, Marseille)</i>
0925-0955	<b>Coffee Break</b>
0955-1040	<b>Panel 6: Facilitating Access to PrEP from Bench to Clinic</b> <b>Moderator:</b> <i>Chris Duncombe, MD, PhD* (Gates Foundation)</i> <i>Jim Rooney, MD* (Gilead Sciences)</i> <i>Ron d'Amico, MD* (Abbott Laboratories)</i> <i>Additional Pharma Reps TBA</i>
1040-1140	<b>Discussion</b>
1140-1200	<b>Plenary 9: Behavior and PrEP - Risk Compensation and Other Concerns</b> <i>K. Rivet Amico, PhD* (University of Connecticut)</i>
1200-1220	<b>Plenary 10: Managing PrEP-Related Safety Concerns</b> <i>Veronica Miller, PhD* (Forum for Collaborative HIV Research)</i>
1220-1240	<b>Plenary 11: Cost-Benefit Analysis of Universal versus Selective PrEP</b> <i>Bruce Schackman, PhD* (Weill Cornell Medical College)</i>
1240-1410	<b>Lunch</b>
1410-1455	<b>Panel 7: Community, Provider, Operational, and Regulatory Perspectives on PrEP Implementation</b> <b>Moderator:</b> <i>Yuzef Azad* (National AIDS Trust, United Kingdom)</i> <i>Claire Foreman* (London HIV Consortium) - access, cost from public sector payor</i> <i>Michael Horberg, MD* (Kaiser Permanente) - access, cost from private sector payor</i> <i>Benjamin Young, MD, PhD* (IAPAC) - workforce</i> <i>Jim Pickett* (AIDS Foundation of Chicago) - community</i> <i>EMEA representative - approval, surveillance</i>
1455-1555	<b>Discussion</b>
1555-1625	<b>Coffee Break</b>

<b>TasP and PrEP</b>	
<b>1625-1645</b>	<b>Plenary 12: IAPAC Adherence Guidelines - Addressing the Achilles' Heel of TasP and PrEP</b> <i>Jean Nachega, MD, PhD* (Johns Hopkins University/Stellenbosch University)</i>
<b>1645-1705</b>	<b>Plenary 13: Implementation Science - Building the <u>Prevention 2.0</u> Ship As We Sail Her</b> <i>Kevin Fenton, MD, PhD* (US CDC)</i>
<b>1705-1725</b>	<b>Plenary 14: Combination Prevention - Seizing the Moment to Curb an Pandemic</b> <i>José M. Zuniga, PhD, MPH* (IAPAC)</i>
<b>1725-1800</b>	<b>Rapporteur Session &amp; Closing Remarks</b>

*\* Confirmed as of 8 May 2012*